Bearbmagovva

Update on the development of lurasidone as a treatment for patients with acute schizophrenia

Norio Yasui-FurukoriDepartment of Neuropsychiatry, Hirosaki University School of Medicine, Aomori, JapanAbstract: Lurasidone is a novel benzisothiazole antipsychotic drug for the treatment of schizophrenia. Of the antipsychotic drugs, lurasidone has the highest affinity for the 5-hydroxytryptamine (...

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Yasui-Furukori N (Dahkki)
Materiálatiipa:	Girji
Almmustuhtton:	Dove Medical Press, 2012-05-01T00:00:00Z.
Fáttát:	article
Liŋkkat:	Connect to this object online.
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
Dahkki: Miura I, et al.
Almmustuhtton: (2023)

Lurasidone for the treatment of schizophrenia in adult and paediatric populations
Dahkki: Teresa Guilera, et al.
Almmustuhtton: (2023)

Clinical potential of lurasidone in the management of schizophrenia
Dahkki: Samalin L, et al.
Almmustuhtton: (2011)

Identification of clinical phenotypes in schizophrenia: the role of lurasidone
Dahkki: Marco Andrea Riva, et al.
Almmustuhtton: (2021)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
Dahkki: Jia Liu, et al.
Almmustuhtton: (2022)

Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom
Dahkki: Amy Dymond, et al.
Almmustuhtton: (2022)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
Dahkki: Jia Liu, et al.
Almmustuhtton: (2022)

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
Dahkki: Norio Yasui‐Furukori, et al.
Almmustuhtton: (2020)

Antipsychotic treatments; Focus on lurasidone
Dahkki: Tomiki eSumiyoshi
Almmustuhtton: (2013)

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis
Dahkki: John W. Newcomer, et al.
Almmustuhtton: (2018)

Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
Dahkki: Taro Kishi, et al.
Almmustuhtton: (2020)

Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive and cognitive symptoms in schizophrenia, and dual psychosis
Dahkki: María Teresa Guarro Carreras, et al.
Almmustuhtton: (2024)

Differences in self‐reported psychotic symptoms between patients with autism spectrum disorder and those with schizophrenia
Dahkki: Momoka Yamada, et al.
Almmustuhtton: (2023)

Microneedle-Assisted Transdermal Delivery of Lurasidone Nanoparticles
Dahkki: Ariana Radmard, et al.
Almmustuhtton: (2024)

Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels
Dahkki: Minami Tasaki, et al.
Almmustuhtton: (2021)

Management of bipolar I depression: clinical utility of lurasidone
Dahkki: Findlay LJ, et al.
Almmustuhtton: (2015)

Lurasidone‐induced hyperosmolar hyperglycemic syndrome: A case report
Dahkki: Shota Hanyu, et al.
Almmustuhtton: (2022)

Lurasidone versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study
Dahkki: Xiangyuan Diao, et al.
Almmustuhtton: (2022)

Lurasidone Suppresses Rapid Eye Movement Sleep and Improves Sleep Quality in Rats
Dahkki: Takeshi Murai, et al.
Almmustuhtton: (2014)

Factors associated with the initiation of laxative use in the same patients with schizophrenia over a 20‐year period: Retrospective cohort study
Dahkki: Yasushi Kawamata, et al.
Almmustuhtton: (2024)

Wearables in Schizophrenia: Update on Current and Future Clinical Applications
Dahkki: Lakshan N Fonseka, et al.
Almmustuhtton: (2022)

NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro
Dahkki: Michael T. Sapko, et al.
Almmustuhtton: (2024)

Improving Lurasidone Hydrochloride's Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin
Dahkki: María Elena Gamboa-Arancibia, et al.
Almmustuhtton: (2023)

A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
Dahkki: Taro Kishi, et al.
Almmustuhtton: (2023)

A case of panic attack developing after THC‐O acetate inhalation using an e‐cigarette device
Dahkki: Norio Sugawara, et al.
Almmustuhtton: (2023)

Changes in suicidal ideation during treatment among patients with major depressive disorder: A 6‐month naturalistic follow‐up study
Dahkki: Aoi Sato, et al.
Almmustuhtton: (2024)

Projections of psychiatrists' distribution for patients in Japan: a utilization-based approach
Dahkki: Norio Sugawara, et al.
Almmustuhtton: (2021)

Eye movement characteristics in schizophrenia: A recent update with clinical implications
Dahkki: Kentaro Morita, et al.
Almmustuhtton: (2020)

Risperidone ISM: review and update of its usefulness in all phases of schizophrenia
Dahkki: Thomas Messer, et al.
Almmustuhtton: (2024)

Schizophrenia Treatment The New Facets
Almmustuhtton: (2016)

Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
Dahkki: Taro Kishi, et al.
Almmustuhtton: (2020)

A pregnant woman who experienced auditory hallucinations concurrent with hyperemesis gravidarum: A case report
Dahkki: Hiroaki Okayasu, et al.
Almmustuhtton: (2021)

Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia"
Dahkki: Ken Inada, et al.
Almmustuhtton: (2022)

Acute overdose of antipsychotics and antidepressants by patient with paranoid schizophrenia - a case report
Dahkki: Anna Katarzyna Orzeł, et al.
Almmustuhtton: (2019)

Acute overdose of antipsychotics and antidepressants by patient with paranoid schizophrenia - a case report
Dahkki: Anna Katarzyna Orzeł, et al.
Almmustuhtton: (2019)

Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study
Dahkki: Shusuke Numata, et al.
Almmustuhtton: (2021)

Association between the examination rate of treatment‐resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study
Dahkki: Norio Yasui‐Furukori, et al.
Almmustuhtton: (2022)

The influence of physical activity on the health and treatment of schizophrenia patients
Dahkki: Katarzyna Kuśmierczyk, et al.
Almmustuhtton: (2024)

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders
Dahkki: Saruwatari J, et al.
Almmustuhtton: (2014)

The role of lumateperone in the treatment of schizophrenia
Dahkki: Alveena Batool Syed, et al.
Almmustuhtton: (2021)